Skip to main content

Advertisement

Table 2 Results of proportional hazard Cox regression models for overall survival among overweight and obese patients in comparison with normal BMI patients

From: The impact of baseline body mass index on clinical outcomes in metastatic breast cancer: a prospective study

Variable Univariate Multivariate
HRa (95% CI) P value HRa (95% CI) P value
All patients
Overweight 0.54 (0.29–0.98) 0.044 0.51 (0.26–0.99) 0.047
Obese 0.55 (0.29–1.02) 0.059 0.54 (0.26–1.15) 0.109
Age (years) ≥ 50
Overweight 0.31 (0.06–1.56) 0.155 0.28 (0.05–1.52) 0.140
Obese 0.37 (0.08–1.81) 0.221 0.26 (0.05–1.45) 0.125
Age (years) < 50
Overweight 0.69 (0.35–1.35) 0.279 0.57 (0.28–1.17) 0.128
Obese 0.79 (0.35–1.78) 0.569 0.60 (0.22–1.60) 0.309
≥2 metastatic sites
Overweight 0.73 (0.34–1.58) 0.432 0.67 (0.28–1.56) 0.349
Obese 1.28 (0.54–3.07) 0.574 1.43 (0.54–3.83) 0.473
1 metastatic site
Overweight 0.37 (0.14–1.01) 0.051 0.49 (0.13–1.80) 0.279
Obese 0.36 (0.14–0.92) 0.033 0.31 (0.07–1.25) 0.099
≥ 2nd line
Overweight 0.47 (0.21–1.05) 0.065 0.37 (0.15–0.92) 0.032
Obese 0.49 (0.21–1.15) 0.100 0.48 (0.17–1.34) 0.163
1st line
Overweight 0.53 (0.21–1.35) 0.183 0.97 (0.36–2.64) 0.953
Obese 0.48 (0.18–1.29) 0.146 1.60 (0.35–7.39) 0.549
Hormone receptors (−)
Overweight 0.68 (0.25–1.85) 0.450 0.71 (0.23–2.17) 0.548
Obese 0.57 (0.21–1.54) 0.269 1.07 (0.34–3.39) 0.910
Hormone receptors (+)
Overweight 0.60 (0.27–1.33) 0.211 0.46 (0.16–1.28) 0.135
Obese 0.64 (0.26–1.57) 0.335 0.37 (0.10–1.30) 0.120
HER2 (−)
Overweight 0.36 (0.10–1.24) 0.104 0.42 (0.11–1.68) 0.221
Obese 0.52 (0.16–1.69) 0.279 0.58 (0.06–5.14) 0.622
HER2 (+)
Overweight 0.66 (0.30–1.46) 0.307 0.56 (0.24–1.32) 0.188
Obese 0.51 (0.22–1.18) 0.116 0.57 (0.23–1.44) 0.235
  1. aHazard ratios (HR) represent risk of death compared with normal BMI (< 25 kg/m2) patients